Go to content


Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 19 nov 2008 - 15:03
Statutaire naam MDxHealth
Titel LabCorp Introduces MGMT Methylation Testing Service in North America
Bericht Liege (Belgium) – November 19, 2008, 2:00 PM CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that Laboratory Corporation of America® Holdings (LabCorp®) commercially launched its MGMT methylation testing service. LabCorp recently licensed OncoMethylome’s patented MSP and MGMT DNA methylation marker technology for its test. This is the third DNA methylation test overall and the first “personalized medicine” test using technology from OncoMethylome Sciences to become commercially available in North America for clinical use. OncoMethylome Sciences will receive royalty and milestone payments from LabCorp on the sales of the MGMT methylation testing service.